Navigation Tip: Click on blue text that’s underlined and in bold for link to more information.
Greetings!
We hope that theAugust 2019 Hot SHEET newsletterfinds you doing well and enjoying the summer season! In addition to the newsletter, we hope that the following updates and information are of interest to you.
Men with metastatic castration-resistant prostate cancerare invited to consider enrollment in one of two international, Pfizer-sponsored studies of talazoparib, a PARP inhibitor.
TALAPRO-1: A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT).
TALAPRO-2:A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
IRONMANis a registry recruiting 5,000 men with advanced prostate cancer from 9 countries.More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best care to enable men to live the best quality life possible.
The Metastatic Prostate Cancer Project is a nationwide genomic research studyfor men with metastatic and/or advanced prostate cancer. Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries.
BRCA Blueis a program to help educate patients and caregivers about the connection between BRCA gene mutations and prostate cancer. While some people may have heard about BRCA genes and their relationship to breast and ovarian cancers, research has shown a connection to other cancers as well – including prostate cancer. In fact, men who have a BRCA mutation are at a higher risk for developing prostate cancer than men without a BRCA mutation. To learn more about this important gene, please visit BRCAblue.com.
We’re looking forward to hosting the15th Annual SEA Blue Chicago Prostate Cancer Walk & Runon Sunday, September 15, in Lincoln Park! SEA is an acronym for Support, Educate and Advocate; and blue is to prostate cancer as pink is to breast cancer. Register to join us at the event, if possible; or register as a virtual mover at no charge if you will not attend in person and want to help fundraise. For a glimpse into what makes this event so special for so many people, check out the video.
Join PCRI from September 6-8 for the2019 PCRI Prostate Cancer Patient Conferenceand get face to face with prostate cancer experts in every field. Hosted at the Los Angeles Airport Marriott, the PCRI conference is a full-featured educational experience for prostate cancer patients and caregivers. Each day consists of straightforward presentations, extended Q+A sessions, individualized small-group sessions, and a variety of fun and enriching activities to facilitate camaraderie. You can expect to gain a comprehensive knowledge of your disease and become empowered to make the best decisions for your life. Choose your strategy and win the fight! Watch the new promotional video!Register using the code "ustoo" for a discounted patient registration rate of $30.00.
Take care and let us know how we can help you with educational resources, support services and personal connections to others in the prostate cancer community.
All the best,
Chuck Strand, Chief Executive Officer
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
